☆ 4.4 Article

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

BMC HEALTH SERVICES RESEARCH (2023)

Related references

Note: Only part of the references are listed.

Article

Target Trial Emulation: A Design Tool for Cancer Clinical Trials

Sandi A. Kwee et al.

JCO Clinical Cancer Informatics (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data

Devon J. Boyne et al.

Summary: This study aimed to simulate a hypothetical target trial to assess the effect of initiating FOLFIRINOX versus GN within 8 weeks of diagnosis on overall survival in advanced pancreatic cancer patients. The observational cohort study used population-level data from Alberta, Canada. The results showed that FOLFIRINOX had a longer median overall survival compared to GN, with an adjusted difference of 3.2 months and a mortality hazard ratio of 0.78. These findings support the initiation of FOLFIRINOX for improved overall survival in patients with advanced pancreatic cancer.

ANNALS OF EPIDEMIOLOGY (2023)

Add to Collection

Article Hematology

Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A

Clifford Goodman et al.

Summary: With the emergence of gene therapies, there are increased clinical and economic uncertainties for payers, providers, patients, and manufacturers. This raises interest in risk-sharing arrangements, such as alternative payment models (APMs). This article examines the applicability of APMs in the context of emerging gene therapies for haemophilia A.

HAEMOPHILIA (2022)

Add to Collection

Editorial Material Ethics

Double bad luck: Should rare diseases get special treatment?

Adam Hutchings

JOURNAL OF MEDICAL ETHICS (2022)

Add to Collection

Article Economics

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

Renske M. T. ten Ham et al.

Summary: This study is the first empirical review of HTA using the EUnetHTA Core Model to identify and categorize key considerations retrospectively. Results indicate that, besides clinical and cost-effectiveness, social, ethical, and legal domains also play a significant role in the assessment of ATMPs.

VALUE IN HEALTH (2022)

Add to Collection

Article Economics

Consideration of quality of life in the health technology assessments of rare disease treatments

Elena Nicod et al.

Summary: Challenges exist with PRO evidence and HSUVs in rare diseases due to small populations and lack of disease knowledge. The study highlights the need for improved development and use of PRO/HSUVs, as well as the importance of other forms of evidence and expert input in supporting appraisal of uncertain or missing evidence.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2022)

Add to Collection

Article Economics

Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence

Oriana Ciani et al.

Summary: In order to facilitate faster patient access to treatments, healthcare technology assessment agencies and payers are increasingly relying on surrogate endpoints, leading to decision uncertainty. This research analyzes international HTA practices and develops a web-based decision tool to assist HTA agencies and payers in handling surrogate endpoint evidence.

HEALTH ECONOMICS (2022)

Add to Collection

Review Health Care Sciences & Services

Design and analysis features used in small population and rare disease trials: A targeted review

Giles Partington et al.

Summary: Frequentist trials in rare disease/small population trials often require unfeasibly large sample size, while Bayesian trials can reduce sample size by using informative priors. Most frequentist trials did not reach the target sample size. Bayesian methods offer promising solutions for such trials but are underutilized.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2022)

Add to Collection

Review Economics

A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients

Amy Gye et al.

Summary: This review aimed to identify the sources of variability in cost-effectiveness analyses of CAR-T therapies for different patient populations. The study found that while there was some consistency in the clinical evidence and economic models used, the outcomes varied, especially in young patients. The long-term treatment benefit in young patients was associated with greater uncertainty due to potential lifelong benefits with cell and gene therapies.

VALUE IN HEALTH (2022)

Add to Collection

Review Pharmacology & Pharmacy

A systematic review of economic evaluations of advanced therapy medicinal products

Huw Lloyd-Williams et al.

Summary: Economic evaluations of advanced therapy medicinal products (ATMPs) have shown some evidence of cost-effectiveness, but are associated with significant uncertainty and bias. Products such as chimeric antigen receptor T-cell therapy, gene therapy, and tissue-engineered products have been identified as potentially cost-effective, but with limitations in long-term outcomes and evidence on health state utilities.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Managing access to advanced therapy medicinal products: Challenges for NHS Wales

Andrew R. Champion et al.

Summary: Advanced Therapy Medicinal Products have the potential to transform care pathways, but with high costs and associated financial and healthcare risks, Wales is working to introduce these medicines to ensure patient access is maintained.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe

Sean Tunis et al.

Summary: Emerging cell and gene therapies market access landscape shows that US health plans tend to apply coverage restrictions more often, while European and Canadian HTA bodies recommend access to fewer therapies, reflecting a more stringent approach towards these treatments.

HEALTH POLICY (2021)

Add to Collection

Article Economics

Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach

Darius N. Lakdawalla et al.

Summary: This study aims to reconcile cost-effectiveness analysis (CEA) with economic theory by allowing diminishing returns to health and aligning CEA with health economics literature. The research found that optimal cost-effectiveness thresholds should systematically rise for more severe diseases, impacting the practice of CEA significantly.

VALUE IN HEALTH (2021)

Add to Collection

Review Economics

Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision

Simone A. Huygens et al.

Summary: The study aimed to discuss the methodological challenges of evaluating gene therapies and their implications by examining four economic evaluations of voretigene neparvovec for the treatment of RPE65-mediated inherited retinal disease, revealing significant impact of different methodological choices on cost-effectiveness results.

PHARMACOECONOMICS (2021)

Add to Collection

Article Economics

Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations

Louis P. Garrison et al.

Summary: Assessing the value of gene therapy for hemophilia poses methodological challenges due to immature evidence on the durability of benefits, lack of definition and valuation of cure for chronic diseases, absence of randomized controlled trials, and limitations of traditional quality of life measures. To address these challenges, leveraging expert clinical opinion, using external controls, adjusting cost offsets, considering outcome-based contracts, and presenting different perspectives are recommended.

VALUE IN HEALTH (2021)

Add to Collection

Article Pharmacology & Pharmacy

Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries

Lucia Gozzo et al.

Summary: Despite being centrally approved, there are differences among European countries in terms of health technology assessment (HTA), particularly when it comes to evaluating the therapeutic value of ATMPs. While there is often disagreement on clinical assessment, access to ATMPs is usually guaranteed with varying timing and limitations.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Cell & Tissue Engineering

The use of innovative payment mechanisms for gene therapies in Europe and the USA

Jesper Jorgensen et al.

Summary: Innovative reimbursement mechanisms are increasingly used for gene therapies in Europe, while the usage is more limited in the USA. Decision makers in different countries face varying incentives and challenges in managing uncertainties around the long-term therapeutic potential of gene therapies.

REGENERATIVE MEDICINE (2021)

Add to Collection

Review Economics

Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies

Giulia Fornaro et al.

Summary: This study conducted a scoping review on the option value of healthcare technologies, identifying different definitions and relevant conceptual aspects, as well as proposing methods for its incorporation in economic evaluations. The review found that estimates of the total value of technologies, including option value, varied widely in empirical studies, ranging from +7% to +469% of their conventional value. Future work should focus on developing and validating reliable methods for estimating option value in economic evaluations.

VALUE IN HEALTH (2021)

Add to Collection

Article Economics

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel

Karen M. Facey et al.

Summary: This research reviews the implementation of outcomes-based managed entry agreements (OBMEAs) in the European Union, Australia, and Canada for two case studies, focusing on rare disease treatments. Various types of OBMEAs were identified, with agreements generally made between marketing authorization holders and payers, sometimes involving expert physicians. Collaboration among jurisdictions, sharing of processes and data, and the establishment of an international public portal were suggested to improve the implementation of OBMEAs for rare disease treatments.

PHARMACOECONOMICS (2021)

Add to Collection

Review Economics

Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review

Joseph Khoa Ho et al.

Summary: This review summarized evidence on the cost effectiveness of potentially curative gene therapies, with most studies evaluating chimeric antigen receptor T-cell therapies using Markov or partitioned survival models. While gene therapies were more effective than comparators, their high costs meant that not all were considered cost effective. Choice of comparator and assumptions about long-term effectiveness had significant impacts on cost-effectiveness estimates.

PHARMACOECONOMICS (2021)

Add to Collection

Review Health Care Sciences & Services

Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies

Michal Pochopien et al.

Summary: The paper discusses the impact of differentiated severity and unmet needs of genetic diseases on the economic analysis of GTs.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)

Add to Collection

Article Pharmacology & Pharmacy

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy

Entela Xoxi et al.

Summary: Italy has a well-established system of national registries to support managed entry agreements and monitor innovative medicinal products with clinical and economic uncertainties, ensuring appropriate use and best value for money. The technological architecture of the registries is funded by pharmaceutical companies but governed by the national medicines agency.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Public, Environmental & Occupational Health

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries-The Case of Bulgaria, Romania, and Poland

Maria Kamusheva et al.

Summary: Low- and middle-income countries face various challenges in assessing advanced therapies through health technology evaluation, such as high treatment costs, uncertainty in clinical efficacy, and a lack of qualified health economists. Each country should consider implementing reliable and nationally-oriented HTA programs, as well as providing adequate financial support for these therapies.

FRONTIERS IN PUBLIC HEALTH (2021)

Add to Collection

Article Health Care Sciences & Services

Examining the impact of different country processes for appraising rare disease treatments: a case study analysis

Amanda Whittal et al.

Summary: This study examined the impacts of different appraisal processes for two rare disease treatments, finding that countries with separate or adapted processes had more consistent approaches for managing RDT-related issues during appraisal, creating more transparency in decision-making.

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2021)

Add to Collection

Article Health Policy & Services

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?

Virginia Ronco et al.

Summary: The reimbursement status of ATMPs varies across the European Major five (EU5) countries, with CAR-T being reimbursed in all countries. Outcome-based Managed Entry Agreements (MEAs) are extensively used for ATMPs. Extra funds for hospitals managing ATMPs are only provided in Germany, with additional funding in France.

JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions

Eline van Overbeeke et al.

Summary: Market access challenges for gene therapy medicinal products (GTMPs) vary depending on the therapy being developed, the country seeking market access, and the efforts made by developers, regulators, and payers to overcome these barriers. This review highlights the importance of alerting developers to the challenges associated with GTMP marketing authorization and how to address them.

DRUG DISCOVERY TODAY (2021)

Add to Collection

Article Genetics & Heredity

Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches

Elena Nicod et al.

ORPHANET JOURNAL OF RARE DISEASES (2020)

Add to Collection

Article Economics

Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies

Aris Angelis et al.

PHARMACOECONOMICS (2020)

Add to Collection

Review Economics

A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature

Renske M. T. ten Ham et al.

VALUE IN HEALTH (2020)

Add to Collection

Review Pharmacology & Pharmacy

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies

Sissel Michelsen et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Editorial Material Economics

Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment

Elisabete Goncalves

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)

Add to Collection

Article Economics

HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies

Doug Coyle et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)

Add to Collection

Editorial Material Economics

Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness

Lisa A. Prosser et al.

PHARMACOECONOMICS (2019)

Add to Collection

Article Health Care Sciences & Services

Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold

Louis P. Garrison et al.

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2019)

Add to Collection

Article Economics

Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case

Julia F. Slejko et al.

VALUE IN HEALTH (2019)

Add to Collection

Article Economics

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy

Michael F. Drummond et al.

VALUE IN HEALTH (2019)

Add to Collection

Article Economics

New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?

Steven D. Pearson et al.

VALUE IN HEALTH (2019)

Add to Collection

Meeting Abstract Economics

AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)

I Diakite et al.

VALUE IN HEALTH (2019)

Add to Collection

Editorial Material Economics

A Beginner's Guide to Understanding Curative Therapies

Don Husereau et al.

VALUE IN HEALTH (2019)

Add to Collection

Article Economics

Are Global Health Systems Ready for Transformative Therapies?

Eric Faulkner et al.

VALUE IN HEALTH (2019)

Add to Collection

Article Economics

Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions

Rick A. Vreman et al.

VALUE IN HEALTH (2019)

Add to Collection

Review Pharmacology & Pharmacy

Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications

Marta Carvalho et al.

DRUG DISCOVERY TODAY (2019)

Add to Collection

Review Pharmacology & Pharmacy

Methods for the analysis of multiple endpoints in small populations: A review

Robin Ristl et al.

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2019)

Add to Collection

Article Economics

Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare

Bengt Jonsson et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)

Add to Collection

Article Economics

Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]

Darius N. Lakdawalla et al.

VALUE IN HEALTH (2018)

Add to Collection

Article Genetics & Heredity

Applicability and added value of novel methods to improve drug development in rare diseases

Marian Mitroiu et al.

ORPHANET JOURNAL OF RARE DISEASES (2018)

Add to Collection

Article Economics

Comparing Increments in Utility of Health: An Individual-based Approach

Matthew Taylor et al.

VALUE IN HEALTH (2017)

Add to Collection

Article Hematology

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump et al.

BLOOD (2017)

Add to Collection

Article Public, Environmental & Occupational Health

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available

Miguel A. Hernan et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)

Add to Collection

Letter Biotechnology & Applied Microbiology

Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework

Oriana Ciani et al.

NATURE REVIEWS DRUG DISCOVERY (2016)

Add to Collection

Article Economics

A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France

Michael Drummond et al.

PHARMACOECONOMICS (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.